Clinical Context
A typical patient is an adult with a hematologic malignancy such as multiple myeloma, ovarian cancer with intraperitoneal chemotherapy plan, or retinoblastoma where melphalan is indicated. The patient arrives to an oncology infusion center or hospital outpatient department for administration of J9245 (melphalan hydrochloride, 50 mg). Pre-treatment workflow includes verification of diagnosis and chemotherapy order, review of prior labs (complete blood count, renal and hepatic function), informed consent, and calculation of dose based on body surface area or protocol. Pharmacy prepares the drug under sterile technique and documents lot number and expiration; waste is recorded if partial vials are discarded. Nursing performs baseline assessment, places appropriate vascular access (peripheral IV, implanted port, or intra-arterial/intravitreal access depending on indication), initiates antiemetic prophylaxis as indicated, and administers the melphalan per protocol. Post-infusion monitoring includes vital signs, assessment for extravasation, and documentation of any immediate adverse effects. Typical sites of service are hospital outpatient infusion centers, physician offices with accredited infusion capabilities, ambulatory infusion centers, or operating rooms/interventional suites for intra-arterial or intravitreal administration. Billing uses J9245 per 50 mg vial; applicable modifiers reflect circumstances such as professional or facility billing, drug wasted, patient status, or unusual services. Documentation must include diagnosis linking to chemotherapy intent, ordered dose, lot number, administration route, site of service, and any applicable modifier rationale.